N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway

N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway

Abstract Background MYCN amplification or N-Myc overexpression is found in approximately 40% NEPC and up to 20% CRPC patients. N-Myc has been demonstrated to drive disease progression and hormonal therapeutic resistance of NEPC/CRPC. Here, we aim to identify the molecular mechanisms underlying the N...

Full description

Bibliographic Details
Main Authors: Yu Yin, Lingfan Xu, Yan Chang, Tao Zeng, Xufeng Chen, Aifeng Wang, Jeff Groth, Wen-Chi Foo, Chaozhao Liang, Hailiang Hu, Jiaoti Huang
Format: Article
Language:English
Published: BMC 2019-01-01
Series:Molecular Cancer
Subjects:
Neuroendocrine
ATM
Senescence
ATM inhibitor
EZH2
Online Access:http://link.springer.com/article/10.1186/s12943-019-0941-2

Internet

http://link.springer.com/article/10.1186/s12943-019-0941-2

Similar Items